Loading insider details...
Beta
Latest Form 4 (Aug 11, 2026): Conversion of 3,117,664 LTGO shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | Latigo Biotherapeutics, Inc. (LTGO) | Conversion | 3,117,664 | n/a |
| Apr 3, 2026 | ALUMIS INC. (ALMS) | Other (see footnotes) | 1,176,470 | n/a |
| Feb 7, 2026 | Eikon Therapeutics, Inc. (EIKN) | Conversion | 1,340,878 | n/a |
| Jan 13, 2026 | ALUMIS INC. (ALMS) | Purchase | 117,647 | $2.00M |
| Nov 25, 2025 | ALUMIS INC. (ALMS) | Purchase | 72,212 | $532.9K |
| Nov 20, 2025 | ALUMIS INC. (ALMS) | Purchase | 50,000 | $280.0K |
| May 7, 2025 | ALUMIS INC. (ALMS) | Purchase | 25,000 | $115.5K |
| Jul 4, 2024 | ALUMIS INC. (ALMS) | Conversion | 1,944,577 | n/a |
| Apr 5, 2024 | Kinnate Biopharma Inc. (KNTE) | Disposition to Issuer | 9,671,643 | n/a |
| Nov 3, 2021 | Aclaris Therapeutics, Inc. (ACRS) | Other (see footnotes) | 1,954,904 | n/a |